AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2024
Categories |
Back to Blog
Market Overview:
Bronchiectasis is a chronic lung disease characterized by abnormal dilatation of the bronchi. This occurs due to inflammation and scarring of the bronchial walls resulting in impaired mucus clearance and recurrent infections of the lungs. The major drugs used for managing bronchiectasis include antibiotics, bronchodilators, mucolytics and anti-inflammatory drugs. Key antibiotic classes used include aminoglycosides, macrolides and quinolones. Market Dynamics: The growth of the bronchiectasis drugs market is majorly driven by the increasing prevalence of bronchiectasis. According to the British Lung Foundation, over 225,000 people in the UK have bronchiectasis. Other key drivers include rising geriatric population which are at higher risk of developing the condition and increasing adoption of targeted drug therapies. The availability of novel drug formulations with enhanced efficacy and improved safety profiles compared to conventional drugs is also fueling the market growth. For instance, the approval of inhaled formulations of antibiotics for management of bronchiectasis offer better lung penetration and fewer systemic side effects compared to oral antibiotics. Segment Analysis The bronchiectasis drugs market is segmented into antibiotics, expectorants and bronchodilators. The antibiotics segment currently dominates the bronchiectasis drugs market due to rising prevalence of bronchiectasis caused due to frequent respiratory infections. Antibiotics help in reducing infected mucus and bacteria accumulation in lungs, thereby, significantly improving symptoms. PEST Analysis Political: Governments across various countries are increasingly focusing on improving healthcare infrastructure and funding for rare disease treatment. This is expected to positively impact the bronchiectasis drugs market. Economic: Rising healthcare spending coupled with growing per capita income is expected to drive market growth. However, high costs of branded drugs may restraint the market to some extent. Social: Increasing awareness about rare diseases like bronchiectasis through patient support organizations and advocacy groups is leading to early diagnosis and treatment seeking behavior. Technological: Continuous development of improved nebulizers, inhalers and other drug delivery devices are enhancing patient adherence to medication and ability to self-administer treatment. The global Bronchiectasis Drugs Market Demand is estimated to be valued at US$ 303.8 Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Key Takeaways The global bronchiectasis drugs market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing incidence of chronic respiratory diseases and growing geriatric population. The North America bronchiectasis drugs market currently dominates with the highest market share owing to well-developed healthcare infrastructure and provider reimbursements in countries like the US and Canada. Key players operating in the bronchiectasis drugs market incorporates GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Sanofi S.A., Sunovion Pharmaceuticals Inc., Mylan N.V., Cipla Ltd., Grifols S.A., Insmed Incorporated, Arbor Pharmaceuticals LLC. The key players are focusing on new product launches and approvals to strengthen their market presence. For more insights, read- https://www.dailyprbulletin.com/bronchiectasis-drugs-market-size-market-share-analysis/
0 Comments
Read More
Leave a Reply. |